Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
45 Results for "
ROS aggregation
" in MedChemExpress (MCE) Product Catalog:
Products (45)
45 Results for "ROS aggregation" in MCE Product Catalog:
Cat. No.: HY-D1468
CAS No.: 2555045-67-3
Target:
Research Areas:
Phototherapeutic agent-1 is a multi-modal light diagnosis agent with aggregation-induced emission properties. have certain Phototherapeutic agent-1 has certain reactive oxygen species (ROS) generation capacity in illumination condition. Phototherapeutic agent-1 can effectively kill cancer cells and tumor tissue .
Cat. No.: HY-143413
CAS No.: 2745118-93-6
Target:
Research Areas:
BuChE-IN-2 is an excellent butyrylcholinesterase (BuChE) inhibitor (IC50s of 1.28 μM and 0.67 μM for BuChE and NO). BuChE-IN-2 can inhibit the aggregation of Aβ, ROS formation and chelate Cu 2+, exhibiting proper blood-brain barrier (BBB) penetration. BuChE-IN-2 has potential to research Alzheimer’s disease .
Cat. No.: HY-173144
Target:
Cholinesterase (ChE) Reactive Oxygen Species (ROS) Interleukin Related Lactate Dehydrogenase Amyloid-β
Research Areas:
AChE-IN-85 (Compound 7k) is an AChE inhibitor with an IC50 of 0.083 μM. AChE-IN-85 can inhibit the release of NO, the production of TNF-α and IL-1β, the levels of LDH and ROS, as well as the aggregation of Aβ42. AChE-IN-85 has anti-inflammatory and neuroprotective effects and can be used in the research of diseases such as Alzheimer's disease .
Cat. No.: HY-157440
Research Areas:
AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .
Cat. No.: HY-172782
Target:
Cholinesterase (ChE) Amyloid-β Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)
Research Areas:
BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC50 = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease .
Cat. No.: HY-130237R
CAS No.: 88082-60-4
Category:
Anthocyans other families Flavonoids Phenols Polyphenols Plants
Cat. No.: HY-101200R
CAS No.: 16142-27-1
Synonyms: SIN-1 chloride (Standard)
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Linsidomine (hydrochloride) (Standard) is the analytical standard of Linsidomine (hydrochloride). This product is intended for research and analytical applications. Linsidomine hydrochloride (SIN-1 chloride) is a spontaneous ROS/RNS generator and peroxynitrite donor. Linsidomine hydrochloride is a vasodilator and platelet aggregation inhibitor. Linsidomine hydrochloride induces oxidative stress-induced chondrocyte apoptosis and necrosis. Linsidomine hydrochloride inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of Linsidomine hydrochloride shows protective effects on Zn 2+ treated nerve cells .
Cat. No.: HY-159898
Target:
Free Radical Scavengers Cholinesterase (ChE) Amyloid-β Tau Protein NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) Mitochondrial Metabolism
Research Areas:
AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model .
Cat. No.: HY-158978
Research Areas:
Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC50=0.14 μM), butyrylcholinesterase (BChE, IC50=11.6 μM), monoamine oxidase B (MAO B, IC50=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .
Cat. No.: HY-N2515R
CAS No.: 494753-69-4
Target:
Cat. No.: HY-N0353R
CAS No.: 13657-68-6
Synonyms: (+)-Curdione (Standard)
Cat. No.: HY-180997
Target:
Research Areas:
Aβ aggregation-IN-5 is a brain-penetrant amyloid-β aggregation inhibitor. Aβ aggregation-IN-5 inhibits Aβ aggregation/oligomerization, rescues cells from AB/ROS toxicity and reduces microglial activation/NO production. Aβ aggregation-IN-5 reduces amyloid burden, neuroinflammation, microglial activation in APP/PSEN1 mice. Aβ aggregation-IN-5 can be used for the research of Alzheimer's disease .
Cat. No.: HY-180843
CAS No.: 3105860-83-8
Research Areas:
Aβ/tau aggregation-IN-4 (Compound D21) is an Aβ/tau aggregation inhibitor. Aβ/tau aggregation-IN-4 promotes the degradation of Aβ40/42 (Aβ40, IC50 = 2.151 μM; Aβ42, IC50 = 3.622 μM). Aβ/tau aggregation-IN-4 shows selective AChE inhibition (IC50: 5.56 μM). Aβ/tau aggregation-IN-4 inhibits MAO-A and MAO-B with IC50s of 0.59 μM and 0.09 μM, respectively. Aβ/tau aggregation-IN-4 suppresses intracellular ROS levels. Aβ/tau aggregation-IN-4 can be used in the research of Alzheimer's disease .
Cat. No.: HY-184816
CAS No.: 2883627-65-2
Research Areas:
α-Synuclein-IN-21 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 1.6 μM. α-Synuclein-IN-21 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks re-aggregation. α-Synuclein-IN-21 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-21 can be used for the research of Parkinson's disease .
Cat. No.: HY-183797
CAS No.: 3094774-72-5
Research Areas:
Antitumor agent-218 is an aggregation-induced emission (AIE)-based photosensitizer. Antitumor agent-218 selectively accumulates in the endoplasmic reticulum, and generates ROS within the endoplasmic reticulum upon irradiation to induce necroptosis of tumor cells. Antitumor agent-218 can be used in cancer-related research .
Cat. No.: HY-117123
CAS No.: 37206-04-5
Category:
Cat. No.: HY-184819
CAS No.: 2883627-56-1
Research Areas:
α-Synuclein-IN-24 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 4.0 μM. α-Synuclein-IN-24 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks reaggregation. α-Synuclein-IN-24 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-24 can be used for the research of Parkinson's disease .
Cat. No.: HY-156898
Research Areas:
NPT100-18A is an αSyn oligomerization inhibitor. NPT10018A rescues cleaved caspase-3 levels to control levels. NPT10018A attenuates mitochondrial oxidative stress probe levels in a compartment-specific manner and, at higher concentrations, increases ATP signals. NPT100-18A can be used for the study of Parkinson’s disease (PD) .
Cat. No.: HY-182893
CAS No.: 1919889-97-6
Research Areas:
SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a Kd of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD) .
Cat. No.: HY-P11902
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
